Tag: vaccine

Codexis reports record quarterly revenue thanks to COVID-19 Pfizer vaccine enzyme order

Codexis reports record quarterly revenue thanks to COVID-19 Pfizer vaccine enzyme order

November 7, 2021 |

In California, Codexis, Inc., enzyme engineering company, provided a business update with their Sustainable Manufacturing business demonstrating “remarkable growth, as we significantly executed against the large enzyme orders we received from Pfizer to support its COVID-19 antiviral therapeutic candidate” as well as strong results in the faster-to-market food sector, including enzyme sales for Tate & […]

Read More

Amyris sees promising results for intranasal RNA/NLC vaccine

Amyris sees promising results for intranasal RNA/NLC vaccine

August 22, 2021 |

In California, Amyris, Inc. achieved promising in-vivo results in a study of its licensed RNA vaccine through intranasal delivery, developed in collaboration with the Infectious Disease Research Institute (IDRI), which means an effective Covid-19 nose spray vaccine could become reality. In-vivo results indicate that, when delivered to the mucosal membranes via intranasal administration, the Amyris/IDRI […]

Read More

Amyris completes 1st major license for RNA COVID vaccine

Amyris completes 1st major license for RNA COVID vaccine

July 3, 2021 |

In California, Amyris, Inc. signed an exclusive license with Nant Africa, LLC relating to the development and use of the RNA COVID vaccine Amyris developed in coordination with the Infectious Disease Research Institute (IDRI). Amyris’ partnership with Nant Africa is of significant value to Amyris as it provides the fastest path to market for the […]

Read More

Dyadic International vaccine candidate moving to human clinical trials

Dyadic International vaccine candidate moving to human clinical trials

March 22, 2021 |

In Florida, Dyadic International says that the company’s initial C1 produced SARS-CoV-2-S-RBD vaccine candidate, DYAI-100, is moving towards an anticipated safety and preliminary efficacy first in human Phase 1 clinical trial. Dyadic has entered into a master services agreement with CR2O, a full-service global contract research organization specializing in vaccinology, to manage preclinical and clinical […]

Read More

Amyris and IDRI enter license for RNA vaccine platform, beginning with COVID-19 vaccine

Amyris and IDRI enter license for RNA vaccine platform, beginning with COVID-19 vaccine

October 25, 2020 |

In California, Amyris, Inc. signed a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI’s RNA vaccine platform, including IDRI’s proprietary nanostructured lipid carrier platform, with Amyris’s semi-synthetic squalene. This has the […]

Read More

Amyris trialing bio-based vaccine adjuvants to replace demand for deep-sea shark livers

Amyris trialing bio-based vaccine adjuvants to replace demand for deep-sea shark livers

October 1, 2020 |

In California, Amyris, Inc. is currently delivering samples to pharmaceutical companies of a sustainable and scalable alternative to shark-based vaccine adjuvants currently used in a number of vaccines, including those directed at influenza and COVID-19. Amyris expects commercialization and production of its alternative squalene for adjuvants in the fourth quarter. Adjuvants are added to vaccines […]

Read More

Amyris Launches Leading Hand Sanitizer and Receives Initial Positive Result for Vaccine Adjuvant

Amyris Launches Leading Hand Sanitizer and Receives Initial Positive Result for Vaccine Adjuvant

March 26, 2020 |

In California comes the news that synthetic biology leader Amyris is stepping out to help fight COVID-19. Amyris may be more well known for its sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, but as you all know, things have changed a lot over the last few months and […]

Read More